Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

ROCHE HOLDING LTD.
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (CHF)
Sales 2018 55 738 M
EBIT 2018 18 495 M
Net income 2018 12 050 M
Debt 2018 4 564 M
Yield 2018 3,87%
Sales 2019 57 506 M
EBIT 2019 19 044 M
Net income 2019 12 710 M
Finance 2019 998 M
Yield 2019 3,96%
P/E ratio 2018 15,50
P/E ratio 2019 14,93
EV / Sales2018 3,55x
EV / Sales2019 3,34x
Capitalization 193 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
05/23 | 05:30pmSpecial Situation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
05/21Roche Presents Positive Results From Hemlibra Trials
DJ
05/21GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Per..
BU
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/16Reducing Use of Roche Drug for Breast Cancer Didn't Hurt Efficacy, Study Says
DJ
05/16ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avasti..
BU
05/16ROCHE : Follow-up Phase III Data Showed Genentech’s Alecensa Helped People..
BU
05/15Roche's Actemra Gets FDA Nod for Pediatric Subcutaneous Use
DJ
05/14ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polya..
BU
05/14GENENTECH : to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in Peop..
BU
05/10Roche's Phase 3 IMblaze370 Study Misses Primary Endpoint
DJ
More news
Sector news : Pharmaceuticals - NEC
01:16aJ&J hit with $21.7 million verdict in another talc asbestos cancer case
RE
12:28aEXCLUSIVE - U.S. WANTS CHINA TO APPR : sources
RE
12:20aWILLIAM ACKMAN : Ackman makes roughly $1 billion bet on Lowe's
RE
05/23Why the world needs more than one Ebola vaccine
RE
05/23SHIRE PLC SHIRE PLC : Block Listing Interim Review
DJ
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 258  CHF
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.194 670
JOHNSON & JOHNSON-11.45%329 663
PFIZER-1.16%208 947
NOVARTIS-6.55%201 263
ROCHE HOLDING LTD.-8.90%194 670
MERCK AND COMPANY3.87%157 248